Zymeworks Inc. (ZYME)

Over the past six months, Zymeworks' stock has been influenced by several events. The Q1 2026 earnings report showed a revenue decline, but the company maintained a strong cash position. The FDA and China's NMPA accepted sBLAs for zanidatamab. Zymeworks secured a $250 million royalty monetization deal and continued its share repurchase program. The company presented clinical data for ZW191 and preclinical data for a RAS-targeting ADC platform. ZYME shares have increased by 61.6% in the last six months and 135% over the past year.

Information regarding specific demand seasonality for Zymeworks, Inc.'s products and services is not available. Demand is primarily driven by unmet medical needs, clinical trial outcomes, regulatory approvals, and market access, rather than typical seasonal patterns.

Zymeworks, Inc. is a global biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases. Their therapeutic platforms include Azymetric™, Drug Conjugate Platforms, EFECT™, and ProTECT. Key product candidates include Zanidatamab (Ziihera®), Zanidatamab Zovodotin, Pasritamig, ZW191, ZW251, ZW220, ZW209, ZW1528, and preclinical candidates like ZW171.

Zymeworks Inc. is headquartered in Vancouver, British Columbia, Canada, and maintains a global presence with 4 sites in 3 countries. Its shareholder base is geographically diverse, with significant representation from the United States, Switzerland, France, and the United Kingdom. The company has strategic partnerships with BeOne Medicines Ltd. for Asia and Jazz Pharmaceuticals Ireland Limited for other territories for the development and commercialization of zanidatamab.

Zymeworks has maintained a positive brand reputation due to clinical progress and strategic financial moves. Analyst sentiment is "Moderate Buy" with a significant upside potential. Clinical and preclinical advancements have been presented at major conferences. Regulatory milestones include FDA Priority Review and China's sBLA acceptance for zanidatamab. Strategic financial management includes a royalty monetization deal and share repurchase program. Leadership changes have been made to align with corporate strategy.

Zymeworks Inc. has high institutional ownership, ranging from 94.62% to 96.89%. Major institutional owners include EcoR1 Capital, LLC, Rubric Capital Management LP, and BlackRock, Inc. Oleg Nodelman is a significant individual insider owner, and EcoR1 Capital LLC is the largest individual shareholder.